Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Karakasis P, Patoulias D, Fragakis N, Mantzoros CS

Metabolism: clinical and experimental22 Dec 2024Cited by 125 (Europe PMC)

PMID39719170DOI10.1016/j.metabol.2024.156113PepBankPUB-39719170

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, liraglutide at 3.0 mg weekly or 1.8 mg daily as printed showed significant weight reduction; its exact comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, liraglutide showed lower body weight; its exact comparison was unstated.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg weekly or 1.8 mg dailyAs given in this study (human).
Source sentences
Summary
Liraglutide, at 3.0 mg weekly or 1.8 mg daily, was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917013
02HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, liraglutide at 3.0 mg weekly or 1.8 mg daily as printed did not significantly reduce lean mass; its exact comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, liraglutide did not significantly reduce lean mass; its exact comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
3.0 mg weekly or 1.8 mg dailyAs given in this study (human).
Source sentences
Summary
Liraglutide, at 3.0 mg weekly or 1.8 mg daily, was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917014
03HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, tirzepatide ranked among the most effective network treatments for body-weight reduction.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, tirzepatide ranked among the most effective treatments for body-weight reduction.
Peptide
Tirzepatide
Outcome
Not applicablebody-weight reduction efficacy rank
Study
n: not reported in source
Comparator
Other network treatments
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg weeklyAs given in this study (human).
Source sentences
Summary
Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917015
04HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, semaglutide ranked among the most effective network treatments for body-weight reduction.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, semaglutide ranked among the most effective treatments for body-weight reduction.
Peptide
Semaglutide
Outcome
Not applicablebody-weight reduction efficacy rank
Study
n: not reported in source
Comparator
Other network treatments
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg weeklyAs given in this study (human).
Source sentences
Summary
Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917016
05HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, tirzepatide ranked among the most effective network treatments for fat-mass reduction.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, tirzepatide ranked among the most effective treatments for fat-mass reduction.
Peptide
Tirzepatide
Outcome
Not applicablefat-mass reduction efficacy rank
Study
n: not reported in source
Comparator
Other network treatments
Outcome group
Body composition · Metabolic and weight
Studied dose
15 mg weeklyAs given in this study (human).
Source sentences
Summary
Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917017
06HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, semaglutide ranked among the most effective network treatments for fat-mass reduction.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, semaglutide ranked among the most effective treatments for fat-mass reduction.
Peptide
Semaglutide
Outcome
Not applicablefat-mass reduction efficacy rank
Study
n: not reported in source
Comparator
Other network treatments
Outcome group
Body composition · Metabolic and weight
Studied dose
2.4 mg weeklyAs given in this study (human).
Source sentences
Summary
Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917018
07HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, tirzepatide ranked among the least effective network treatments for lean-mass preservation.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, tirzepatide ranked among the least effective treatments for lean-mass preservation.
Peptide
Tirzepatide
Outcome
Not applicablelean-mass preservation efficacy rank
Study
n: not reported in source
Comparator
Other network treatments
Outcome group
Body composition · Musculoskeletal
Studied dose
15 mg weeklyAs given in this study (human).
Source sentences
Summary
Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917019
08HumanSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, semaglutide ranked among the least effective network treatments for lean-mass preservation.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, semaglutide ranked among the least effective treatments for lean-mass preservation.
Peptide
Semaglutide
Outcome
Not applicablelean-mass preservation efficacy rank
Study
n: not reported in source
Comparator
Other network treatments
Outcome group
Body composition · Musculoskeletal
Studied dose
2.4 mg weeklyAs given in this study (human).
Source sentences
Summary
Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
Report a problemFND-3971917020

Studies that did not test the peptide alone15

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced body weight (MD -3.55 kg; 95% CI -4.81 to -2.29); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower body weight; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseTotal body weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference in body weight
−3.55 kg
pooled GLP-1RA evidence; 95% CI -4.81 to -2.29; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971917001
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced body weight (MD -3.55 kg; 95% CI -4.81 to -2.29); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower body weight; the exact comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseTotal body weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference in body weight
−3.55 kg
pooled GLP-1RA evidence; 95% CI -4.81 to -2.29; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3971917002
11HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced body weight (MD -3.55 kg; 95% CI -4.81 to -2.29); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower body weight; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseTotal body weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference in body weight
−3.55 kg
pooled GLP-1RA evidence; 95% CI -4.81 to -2.29; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3971917003
12HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced fat mass (MD -2.95 kg; 95% CI -4.11 to -1.79); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower fat mass; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Measurements
Mean difference in fat mass
−2.95 kg
pooled GLP-1RA evidence; 95% CI -4.11 to -1.79; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971917004
13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced fat mass (MD -2.95 kg; 95% CI -4.11 to -1.79); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower fat mass; the exact comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Measurements
Mean difference in fat mass
−2.95 kg
pooled GLP-1RA evidence; 95% CI -4.11 to -1.79; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3971917005
14HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced fat mass (MD -2.95 kg; 95% CI -4.11 to -1.79); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower fat mass; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Measurements
Mean difference in fat mass
−2.95 kg
pooled GLP-1RA evidence; 95% CI -4.11 to -1.79; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3971917006
15HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced lean mass (MD -0.86 kg; 95% CI -1.30 to -0.42); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower lean mass; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
Mean difference in lean mass
−0.86 kg
pooled GLP-1RA evidence; 95% CI -1.30 to -0.42; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971917007
16HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced lean mass (MD -0.86 kg; 95% CI -1.30 to -0.42); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower lean mass; the exact comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
Mean difference in lean mass
−0.86 kg
pooled GLP-1RA evidence; 95% CI -1.30 to -0.42; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3971917008
17HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence showed reduced lean mass (MD -0.86 kg; 95% CI -1.30 to -0.42); the exact pooled comparator was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence showed lower lean mass; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
Mean difference in lean mass
−0.86 kg
pooled GLP-1RA evidence; 95% CI -1.30 to -0.42; exact comparator unspecified
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3971917009
18HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence reported unaffected relative lean mass, defined as percentage change from baseline; the exact comparison was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence reported no relative lean-mass change; its comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeRelative lean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
However, the relative lean mass, defined as percentage change from baseline, was unaffected.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971917010
19HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence reported unaffected relative lean mass, defined as percentage change from baseline; the exact comparison was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence reported no relative lean-mass change; its comparison was unstated.
Peptide
Semaglutide
Outcome
No significant changeRelative lean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
However, the relative lean mass, defined as percentage change from baseline, was unaffected.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3971917011
20HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In reviewed adults with diabetes and/or overweight/obesity, pooled GLP-1RA evidence reported unaffected relative lean mass, defined as percentage change from baseline; the exact comparison was unstated.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, pooled GLP-1 evidence reported no relative lean-mass change; its comparison was unstated.
Peptide
Tirzepatide
Outcome
No significant changeRelative lean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Source sentences
Summary
However, the relative lean mass, defined as percentage change from baseline, was unaffected.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3971917012
21HumanNot a test of Liraglutide aloneSystematic reviewOther
In reviewed adults with diabetes and/or overweight/obesity, lean-mass loss comprised approximately 25% of total weight loss in pooled GLP-1RA evidence; this was not 25% loss of initial lean mass.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, lean tissue accounted for approximately 25% of total weight lost with pooled GLP-1 therapies.
Peptide
Liraglutide
Outcome
Not applicableLean-mass loss share of total weight loss
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
Lean-mass loss share of total weight loss
≈ 25%
pooled GLP-1RA evidence; not a percentage reduction of initial lean mass
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971917021
22HumanNot a test of Semaglutide aloneSystematic reviewOther
In reviewed adults with diabetes and/or overweight/obesity, lean-mass loss comprised approximately 25% of total weight loss in pooled GLP-1RA evidence; this was not 25% loss of initial lean mass.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, lean tissue accounted for approximately 25% of total weight lost with pooled GLP-1 therapies.
Peptide
Semaglutide
Outcome
Not applicableLean-mass loss share of total weight loss
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
Lean-mass loss share of total weight loss
≈ 25%
pooled GLP-1RA evidence; not a percentage reduction of initial lean mass
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3971917022
23HumanNot a test of Tirzepatide aloneSystematic reviewOther
In reviewed adults with diabetes and/or overweight/obesity, lean-mass loss comprised approximately 25% of total weight loss in pooled GLP-1RA evidence; this was not 25% loss of initial lean mass.
In plain wordsIn reviewed adults with diabetes or overweight/obesity, lean tissue accounted for approximately 25% of total weight lost with pooled GLP-1 therapies.
Peptide
Tirzepatide
Outcome
Not applicableLean-mass loss share of total weight loss
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Measurements
Lean-mass loss share of total weight loss
≈ 25%
pooled GLP-1RA evidence; not a percentage reduction of initial lean mass
Source sentences
Summary
GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.
Summary · context
A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024.
Summary · context
Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.
Summary · context
Twenty-two randomized controlled trials (2258 participants) were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3971917023

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.